{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:20:55Z","timestamp":1783682455171,"version":"3.55.0"},"reference-count":10,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012895","name":"Zoetis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The aim of the current study was to understand how the canine heartworm disease preventive ProHeart\u00ae 12 (extended-release injectable moxidectin, PH 12), impacts heartworm preventive purchase compliance and veterinary practice revenue over time compared to monthly heartworm disease preventives. This was a preliminary observational purchase compliance and revenue study based on a retrospective review of transaction data from 4,615 general practices across the United States. The review period was from September 2018 to August 2020. Anonymous transaction records of over 13 million canine patients were analyzed. Of these, only 3.5 million (25.7%) patients purchased any heartworm preventive, as has been presented in other studies. Practices that implemented PH 12 demonstrated the most growth in canine heartworm prevention revenue, patients, and patient compliance levels during the 12-month observation period, compared to previous year. These practices saw year over year growth in percent patients receiving heartworm protection, as well as 10% and 15% growth in the proportion of preventive patients compliant for more than 6 months and 12 months respectively. In contrast, practices that did not bring on PH 12 and only dispensed monthly heartworm preventives saw a decline in the proportion of canine preventive patients that were compliant for more than 6 months. Similarly, PH 12 practices experienced 15% growth in preventive revenue, and practices that did not bring on PH 12 only experienced 3.9% growth in preventive revenue. PH 12 was single-handedly responsible for all growth in patients compliant for more than 6 months in this study. Growth in protection of canine patients with PH 12 proves a helpful tool where mitigation strategies have thus far failed to curb increasing canine heartworm disease prevalence in the US.<\/jats:p>","DOI":"10.1371\/journal.pone.0271058","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T17:35:47Z","timestamp":1660239347000},"page":"e0271058","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["The compliance and revenue benefits of ProHeart Vs monthly heartworm disease preventives in the US"],"prefix":"10.1371","volume":"17","author":[{"given":"Kennedy","family":"Mwacalimba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2576-1493","authenticated-orcid":true,"given":"Kristine","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Moldavchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Sears","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"issue":"39","key":"pone.0271058.ref001","article-title":"Increasing incidence of Dirofilaria immitis in dogs in USA with focus on the southeast region 2013\u20132016.","volume":"11","author":"J Drake","year":"2018","journal-title":"Parasit Vectors"},{"key":"pone.0271058.ref002","unstructured":"AHS. (2019). Heartworm Incidence Maps. Retrieved from American Heartworm Society. Available from: https:\/\/www.heartwormsociety.org\/pet-owner-resources\/incidence-maps"},{"key":"pone.0271058.ref003","unstructured":"AHS. (2018). American Heartworm Society. Retrieved from Current Canine Guidelines for the Prevention, Diagnosis, and Management of Heartworm (Dirofilaria immitis) Infection in Dogs 2018. Available from: https:\/\/www.heartwormsociety.org\/images\/pdf\/2018-AHS-Canine-Guidelines.pdf"},{"key":"pone.0271058.ref004","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.vetpar.2005.04.005","article-title":"The safety-net story about macrocyclic lactone heartworm preventives: A review, an update, and recommendations","author":"JW McCall","year":"2005","journal-title":"Vet Parasitol"},{"key":"pone.0271058.ref005","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.vetpar.2014.08.013","article-title":"Heartworm \u2018lack of effectiveness\u2019 claims in the Mississippi Delta: Computerized analysis of owner compliance\u2013 2004\u20132011.","author":"CE Atkins","year":"2014","journal-title":"Vet Parasitol"},{"key":"pone.0271058.ref006","article-title":"Heartworms, macrocyclic lactones, and the specter of resistance to prevention in the United States.","volume":"138","author":"D Bowman","year":"2012","journal-title":"Parasit Vectors"},{"issue":"369","key":"pone.0271058.ref007","article-title":"ProHeart\u00ae 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12 months.","volume":"12","author":"TL McTier","year":"2019","journal-title":"Parasit Vectors"},{"issue":"1","key":"pone.0271058.ref008","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1524-4733.2006.00139.x","article-title":"A Checklist for Medication Compliance and Persistence Studies.","volume":"10","author":"AM Peterson","year":"2007","journal-title":"Value in Health"},{"key":"pone.0271058.ref009","doi-asserted-by":"crossref","first-page":"602622","DOI":"10.3389\/fvets.2021.602622","article-title":"Pharmacoeconomic Analysis of Heartworm Preventive Compliance and Revenue in Veterinary Practices in the United States.","volume":"8","author":"K Mwacalimba","year":"2021","journal-title":"Front Vet Sci"},{"key":"pone.0271058.ref010","doi-asserted-by":"crossref","first-page":"602907","DOI":"10.3389\/fvets.2020.602907","article-title":"Retrospective Analysis of Heartworm (Dirofilia immitis) Prevention Medication Compliance and Economic Value in Dogs in Veterinary Practices in Australia.","volume":"7","author":"K Mwacalimba","year":"2021","journal-title":"Front Vet Sci"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0271058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T17:36:02Z","timestamp":1660239362000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0271058"}},"subtitle":[],"editor":[{"given":"Angela Monica","family":"Ionica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":10,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0271058","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]}}}